Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Shares Outstanding (Diluted Average): 2016-2017

  • UroGen Pharma's Shares Outstanding (Diluted Average) rose 64.12% to $13.6 million in Q4 2017 from the same period last year, while for Dec 2017 it was $13.6 million, marking a year-over-year increase of 64.12%. This contributed to the annual value of $13.6 million for FY2017, which is 64.12% up from last year.
  • Per UroGen Pharma's latest filing, its Shares Outstanding (Diluted Average) stood at $13.6 million for Q4 2017, which was up 47.89% from $9.2 million recorded in Q2 2017.
  • UroGen Pharma's 5-year Shares Outstanding (Diluted Average) high stood at $13.6 million for Q4 2017, and its period low was $2.3 million during Q2 2016.
  • Moreover, its 2-year median value for Shares Outstanding (Diluted Average) was $8.7 million (2016), whereas its average is $8.4 million.
  • Data for UroGen Pharma's Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 299.19% (in 2017) over the last 5 years.
  • Over the past 2 years, UroGen Pharma's Shares Outstanding (Diluted Average) (Quarterly) stood at $8.3 million in 2016, then spiked by 64.12% to $13.6 million in 2017.
  • Its last three reported values are $13.6 million in Q4 2017, $9.2 million for Q2 2017, and $8.3 million during Q4 2016.